SJOGREN’S SYNDROME MARKET ANALYSIS

Sjogren’s Syndrome Market, by Drug (Antimalarial Quinolines, Cholinergic Agonists, Corticosteroids and Others (Pain Relief Medication and late phase drug)), by type (Primary and Secondary), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Sep 2022
Code : CMI5210
Pages :165
Formats :
Excel and PDF
Industry : Pharmaceutical

Sjogren’s Syndrome MarketSize and Trends

The global Sjogren’s syndrome market is estimated to be valued at US$ 234.6 million in 2022 and expected to exhibit a CAGR of 3.5% over the forecast period (2022-2030).

Increasing robust pipeline of drug is expected to aid in the growth of the global Sjogren’s syndrome market.

Increasing robust pipeline of drug is expected to aid in the growth of the global Sjogren’s syndrome market. For instance, according to data published in July 2022, on Nation Institute of Medicine (NIH),states that a randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study is going on to assess the efficacy and safety of the drug Ianalumab in patients with Sjogren's syndrome and the estimated study completion date is in March 2026.

Figure 1. Global Sjogren’s syndrome Market Share (%) in Terms of Value, by Region, 2022